Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OS Therapies Incorporated (OSTX : AMEX)

• Company Description    OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.81 Daily Weekly Monthly 20 Day Moving Average: 312,398 shares Shares Outstanding: 35.21 (millions) Market Capitalization: $63.74 (millions) Beta: -4.02 52 Week High: $6.48 52 Week Low: $1.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.55% -1.86% 12 Week -18.10% -20.44% Year To Date -57.71% -59.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 115 PULLMAN CROSSING ROAD SUITE 103 - GRASONVILLE,MD 20850 USA ph: 410-297-7793 fax: - ostx@redchip.com http://www.ostherapies.com

• General Corporate Information    Officers Paul A.Romness - Founder; Chairman; President and Chief Executive O Christopher P.Acevedo - Chief Financial Officer John Ciccio - Director Avril McKean Dieser - Director Karim Galzahr - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68764Y207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 35.21 Most Recent Split Date: (:1) Beta: -4.02 Market Capitalization: $63.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -16.67% vs. Previous Quarter: -10.53% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - -251.76 06/30/25 - -258.74 03/31/25 - -344.83 Current Ratio 09/30/25 - 0.56 06/30/25 - 1.03 03/31/25 - 1.16 Quick Ratio 09/30/25 - 0.56 06/30/25 - 1.03 03/31/25 - 1.16 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 0.11 06/30/25 - 0.18 03/31/25 - -0.19 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - - Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©